Search results
Results from the WOW.Com Content Network
200 mg 1x/4–6 weeks Implant: Testosterone: Testopel: Pellet: 50–100 mg 1x/3–6 months Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter.
25–50 mg 1x/6–12 weeks Prasterone enanthate a: Gynodian Depot: Oil solution: 200 mg 1x/4–6 weeks Implant: Testosterone: Testopel: Pellet: 50–100 mg 1x/3–6 months Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per ...
For reference, testosterone enanthate has an elimination half-life of 4.5 days and a mean residence time of 8.5 days and requires frequent administration of approximately once per week. [21] Large fluctuations in testosterone levels result with it, with levels initially being elevated and supraphysiological. [21]
Testosterone enanthate is used primarily in androgen replacement therapy. [4] [15] It is the most widely used form of testosterone in androgen replacement therapy. [4]The medication is specifically approved, in the United States, for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. [16]
A possible cause of incorrect urine test results is the presence of metabolites from other anabolic steroids, though modern urinalysis can usually determine the exact anabolic steroid used by analyzing the ratio of the two remaining nandrolone metabolites.
The "chart" actually consists of a pair of charts: one, the individuals chart, displays the individual measured values; the other, the moving range chart, displays the difference from one point to the next.
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
3 mg 1x/3–4 weeks: 5 mg 1x/3–4 weeks Estradiol benzoate: 0.5 mg 1x/week: 1 mg 1x/week: 1.5 mg 1x/week SC implant: Estradiol: 25 mg 1x/6 months: 50 mg 1x/6 months: 100 mg 1x/6 months Footnotes: a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days ...